FANCD2 Activates Transcription of TAp63 and Suppresses Tumorigenesis

Molecular Cell

Volumn 50, Issue 6, 2013, Pages 908-918

  Park, Eunmi ^a   Kim, Hyungjin ^a   Kim, Jung Min ^a   Primack, Benjamin ^a   Vidal Cardenas, Sofia ^a   Xu, Ye ^a   Price, Brendan D ^a   Mills, Alea A ^b   D'Andrea, Alan D ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FANCONI ANEMIA GROUP D2 PROTEIN; PROTEIN P63; PROTEIN TAP63; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER SUSCEPTIBILITY; CELL AGING; CONTROLLED STUDY; FANCONI ANEMIA; FEMALE; GENE; GENETIC TRANSCRIPTION; MOUSE; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE RAS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; SKIN CANCER; SKIN CARCINOGENESIS; SQUAMOUS CELL CARCINOMA; USP1 GENE;

ANIMALS; CELL AGING; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; DISEASE RESISTANCE; DNA DAMAGE; ENDOPEPTIDASES; FANCONI ANEMIA; FANCONI ANEMIA COMPLEMENTATION GROUP D2 PROTEIN; FEMALE; GENES, RAS; GENES, TUMOR SUPPRESSOR; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASMS, SQUAMOUS CELL; PHOSPHOPROTEINS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; SKIN NEOPLASMS; TRANS-ACTIVATORS; TRANSCRIPTIONAL ACTIVATION; UBIQUITINATION;

EID: 84880768870     PISSN: 10972765     EISSN: 10974164     Source Type: Journal    
DOI: 10.1016/j.molcel.2013.05.017     Document Type: Article

References (48)

1. Alam M., Ratner D. Cutaneous squamous-cell carcinoma. N.Engl. J. Med. 2001, 344:975-983.
2. Alter B.P., Greene M.H., Velazquez I., Rosenberg P.S. Cancer in Fanconi anemia. Blood 2003, 101:2072.
3. Auerbach A.D. Fanconi anemia and its diagnosis. Mutat. Res. 2009, 668:4-10.
4. Bakker S.T., van de Vrugt H.J., Visser J.A., Delzenne-Goette E., van der Wal A., Berns M.A., van de Ven M., Oostra A.B., de Vries S., Kramer P., et al. Fancf-deficient mice are prone to develop ovarian tumours. J.Pathol. 2012, 226:28-39.
5. Bartkova J., Rezaei N., Liontos M., Karakaidos P., Kletsas D., Issaeva N., Vassiliou L.V., Kolettas E., Niforou K., Zoumpourlis V.C., et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006, 444:633-637.
6. Buckley N.E., Conlon S.J., Jirstrom K., Kay E.W., Crawford N.T., O'Grady A., Sheehan K., Mc Dade S.S., Wang C.W., McCance D.J., et al. The DeltaNp63 proteins are key allies of BRCA1 in the prevention of basal-like breast cancer. Cancer Res. 2011, 71:1933-1944.
7. Cohn M.A., Kowal P., Yang K., Haas W., Huang T.T., Gygi S.P., D'Andrea A.D. A UAF1-containing multisubunit protein complex regulates the Fanconi anemia pathway. Mol. Cell 2007, 28:786-797.
8. Crossan G.P., van der Weyden L., Rosado I.V., Langevin F., Gaillard P.H., McIntyre R.E., Gallagher F., Kettunen M.I., Lewis D.Y., Brindle K., et al. Disruption of mouse Slx4, a regulator of structure-specific nucleases, phenocopies Fanconi anemia. Nat. Genet. 2011, 43:147-152. Sanger Mouse Genetics Project.
9. Di Micco R., Fumagalli M., Cicalese A., Piccinin S., Gasparini P., Luise C., Schurra C., Garre' M., Nuciforo P.G., Bensimon A., et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 2006, 444:638-642.
10. Du W., Rani R., Sipple J., Schick J., Myers K.C., Mehta P., Andreassen P.R., Davies S.M., Pang Q. The FA pathway counteracts oxidative stress through selective protection of antioxidant defense gene promoters. Blood 2012, 119:4142-4151.
11. Fekairi S., Scaglione S., Chahwan C., Taylor E.R., Tissier A., Coulon S., Dong M.Q., Ruse C., Yates J.R., Russell P., et al. Human SLX4 is a Holliday junction resolvase subunit that binds multiple DNA repair/recombination endonucleases. Cell 2009, 138:78-89.
12. Garcia-Higuera I., Taniguchi T., Ganesan S., Meyn M.S., Timmers C., Hejna J., Grompe M., D'Andrea A.D. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol. Cell 2001, 7:249-262.
13. Guo X., Keyes W.M., Papazoglu C., Zuber J., Li W., Lowe S.W., Vogel H., Mills A.A. TAp63 induces senescence and suppresses tumorigenesis invivo. Nat. Cell Biol. 2009, 11:1451-1457.
14. Hölzel M., van Diest P.J., Bier P., Wallisch M., Hoatlin M.E., Joenje H., de Winter J.P. FANCD2 protein is expressed in proliferating cells of human tissues that are cancer-prone in Fanconi anaemia. J.Pathol. 2003, 201:198-203.
15. Houghtaling S., Timmers C., Noll M., Finegold M.J., Jones S.N., Meyn M.S., Grompe M. Epithelial cancer in Fanconi anemia complementation group D2 (Fancd2) knockout mice. Genes Dev. 2003, 17:2021-2035.
16. Houghtaling S., Granville L., Akkari Y., Torimaru Y., Olson S., Finegold M., Grompe M. Heterozygosity for p53 (Trp53+/-) accelerates epithelial tumor formation in fanconi anemia complementation group D2 (Fancd2) knockout mice. Cancer Res. 2005, 65:85-91.
17. Hu H., Xia S.H., Li A.D., Xu X., Cai Y., Han Y.L., Wei F., Chen B.S., Huang X.P., Han Y.S., et al. Elevated expression of p63 protein in human esophageal squamous cell carcinomas. Int. J. Cancer 2002, 102:580-583.
18. Kee Y., D'Andrea A.D. Expanded roles of the Fanconi anemia pathway in preserving genomic stability. Genes Dev. 2010, 24:1680-1694.
19. Kemp C.J., Donehower L.A., Bradley A., Balmain A. Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors. Cell 1993, 74:813-822.
20. Kerr J.B., Hutt K.J., Michalak E.M., Cook M., Vandenberg C.J., Liew S.H., Bouillet P., Mills A., Scott C.L., Findlay J.K., Strasser A. DNA damage-induced primordial follicle oocyte apoptosis and loss of fertility require TAp63-mediated induction of Puma and Noxa. Mol. Cell 2012, 48:343-352.
21. Keyes W.M., Wu Y., Vogel H., Guo X., Lowe S.W., Mills A.A. p63 deficiency activates a program of cellular senescence and leads to accelerated aging. Genes Dev. 2005, 19:1986-1999.
22. Kim J.M., Parmar K., Huang M., Weinstock D.M., Ruit C.A., Kutok J.L., D'Andrea A.D. Inactivation of murine Usp1 results in genomic instability and a Fanconi anemia phenotype. Dev. Cell 2009, 16:314-320.
23. Kim Y., Lach F.P., Desetty R., Hanenberg H., Auerbach A.D., Smogorzewska A. Mutations of the SLX4 gene in Fanconi anemia. Nat. Genet. 2011, 43:142-146.
24. Kim Y., Spitz G.S., Veturi U., Lach F.P., Auerbach A.D., Smogorzewska A. Regulation of multiple DNA repair pathways by the Fanconi anemia protein SLX4. Blood 2013, 121:54-63.
25. Koster M.I., Roop D.R. Transgenic mouse models provide new insights into the role of p63 in epidermal development. Cell Cycle 2004, 3:411-413.
26. Lin Y.L., Sengupta S., Gurdziel K., Bell G.W., Jacks T., Flores E.R. p63 and p73 transcriptionally regulate genes involved in DNA repair. PLoS Genet. 2009, 5:e1000680.
27. Lin H.K., Chen Z., Wang G., Nardella C., Lee S.W., Chan C.H., Yang W.L., Wang J., Egia A., Nakayama K.I., et al. Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature 2010, 464:374-379.
28. Matsushita N., Endo Y., Sato K., Kurumizaka H., Yamashita T., Takata M., Yanagi S. Direct inhibition of TNF-α promoter activity by Fanconi anemia protein FANCD2. PLoS ONE 2011, 6:e23324.
29. Mills A.A., Zheng B., Wang X.J., Vogel H., Roop D.R., Bradley A. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999, 398:708-713.
30. Nijman S.M., Huang T.T., Dirac A.M., Brummelkamp T.R., Kerkhoven R.M., D'Andrea A.D., Bernards R. The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. Mol. Cell 2005, 17:331-339.
31. O'Donnell L., Durocher D. DNA repair has a new FAN1 club. Mol. Cell 2010, 39:167-169.
32. Park E., Zhu F., Liu B., Xia X., Shen J., Bustos T., Fischer S.M., Hu Y. Reduction in IkappaB kinase alpha expression promotes the development of skin papillomas and carcinomas. Cancer Res. 2007, 67:9158-9168.
33. Parmar K., D'Andrea A., Niedernhofer L.J. Mouse models of Fanconi anemia. Mutat. Res. 2009, 668:133-140.
34. Parmar K., Kim J., Sykes S.M., Shimamura A., Stuckert P., Zhu K., Hamilton A., Deloach M.K., Kutok J.L., Akashi K., et al. Hematopoietic stem cell defects in mice with deficiency of Fancd2 or Usp1. Stem Cells 2010, 28:1186-1195.
35. Rocco J.W., Ellisen L.W. p63 and p73: life and death in squamous cell carcinoma. Cell Cycle 2006, 5:936-940.
36. Rocco J.W., Leong C.O., Kuperwasser N., DeYoung M.P., Ellisen L.W. p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell 2006, 9:45-56.
37. Romick-Rosendale L.E., Lui V.W., Grandis J.R., Wells S.I. The Fanconi anemia pathway: Repairing the link between DNA damage and squamous cell carcinoma. Mutat. Res. 2013, 743-744:78-88.
38. Serrano M., Lin A.W., McCurrach M.E., Beach D., Lowe S.W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997, 88:593-602.
39. Smogorzewska A., Matsuoka S., Vinciguerra P., McDonald E.R., Hurov K.E., Luo J., Ballif B.A., Gygi S.P., Hofmann K., D'Andrea A.D., Elledge S.J. Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair. Cell 2007, 129:289-301.
40. Stoepker C., Hain K., Schuster B., Hilhorst-Hofstee Y., Rooimans M.A., Steltenpool J., Oostra A.B., Eirich K., Korthof E.T., Nieuwint A.W., et al. SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype. Nat. Genet. 2011, 43:138-141.
41. Stransky N., Egloff A.M., Tward A.D., Kostic A.D., Cibulskis K., Sivachenko A., Kryukov G.V., Lawrence M.S., Sougnez C., McKenna A., et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011, 333:1157-1160.
42. Suh E.K., Yang A., Kettenbach A., Bamberger C., Michaelis A.H., Zhu Z., Elvin J.A., Bronson R.T., Crum C.P., McKeon F. p63 protects the female germ line during meiotic arrest. Nature 2006, 444:624-628.
43. Svendsen J.M., Smogorzewska A., Sowa M.E., O'Connell B.C., Gygi S.P., Elledge S.J., Harper J.W. Mammalian BTBD12/SLX4 assembles a Holliday junction resolvase and is required for DNA repair. Cell 2009, 138:63-77.
44. Waltermann A., Kartasheva N.N., Dobbelstein M. Differential regulation of p63 and p73 expression. Oncogene 2003, 22:5686-5693.
45. Williams S.A., Maecker H.L., French D.M., Liu J., Gregg A., Silverstein L.B., Cao T.C., Carano R.A., Dixit V.M. USP1 deubiquitinates ID proteins to preserve a mesenchymal stem cell program in osteosarcoma. Cell 2011, 146:918-930.
46. Wong J.C., Alon N., Mckerlie C., Huang J.R., Meyn M.S., Buchwald M. Targeted disruption of exons 1 to 6 of the Fanconi Anemia group A gene leads to growth retardation, strain-specific microphthalmia, meiotic defects and primordial germ cell hypoplasia. Hum. Mol. Genet. 2003, 12:2063-2076.
47. Yamamoto K.N., Kobayashi S., Tsuda M., Kurumizaka H., Takata M., Kono K., Jiricny J., Takeda S., Hirota K. Involvement of SLX4 in interstrand cross-link repair is regulated by the Fanconi anemia pathway. Proc. Natl. Acad. Sci. USA 2011, 108:6492-6496.
48. Yang A., Schweitzer R., Sun D., Kaghad M., Walker N., Bronson R.T., Tabin C., Sharpe A., Caput D., Crum C., McKeon F. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999, 398:714-718.